GlassScriptPhysician profile
Paula Galvan
NPI 1972191013
$2,229.37
in general payments reported to CMS, 2019-2025
24 companies · $951 in 2025
The $951 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $390 · 2024: $889 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589 · Travel and Lodging: $540 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.03 |
| Travel and Lodging | $540.34 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $657.33 | 2025 | |
| Amgen INC. | $353.24 | 2023-2024 | Repatha |
| Cvrx, INC. | $240.93 | 2024 | Barostim Neo System |
| Boston Scientific Corporation | $198.59 | 2023-2025 | Rezum Generator, Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.91 | 2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.51 | 2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $54.75 | 2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $52.34 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $46.29 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $43.22 | 2023 | Verquvo |
| Immunitybio, INC. | $41.02 | 2025 | |
| Abiomed | $40.41 | 2023-2025 | Impella |
| Abbvie INC. | $34.26 | 2025 | |
| Calyxo, INC. | $29.23 | 2025 | Cvac Aspiration System |
| Kiniksa Pharmaceuticals International, Plc | $28.67 | 2024 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $22.89 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.32 | 2024 | |
| Novo Nordisk INC | $20.17 | 2024 | Ozempic, Rybelsus |
| Teleflex LLC | $19.92 | 2025 | Urolift |
| Pfizer INC. | $18.35 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $16.93 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $15.82 | 2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $15.48 | 2024 | |
| Agepha Pharma Fz LLC | $14.79 | 2024 | Lodoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Galvan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.